87 related articles for article (PubMed ID: 16889434)
1. Solubilization of single-wall carbon nanohorns using a PEG-doxorubicin conjugate.
Murakami T; Fan J; Yudasaka M; Iijima S; Shiba K
Mol Pharm; 2006; 3(4):407-14. PubMed ID: 16889434
[TBL] [Abstract][Full Text] [Related]
2. Water-dispersed single-wall carbon nanohorns as drug carriers for local cancer chemotherapy.
Murakami T; Sawada H; Tamura G; Yudasaka M; Iijima S; Tsuchida K
Nanomedicine (Lond); 2008 Aug; 3(4):453-63. PubMed ID: 18694307
[TBL] [Abstract][Full Text] [Related]
3. Dispersion of cisplatin-loaded carbon nanohorns with a conjugate comprised of an artificial peptide aptamer and polyethylene glycol.
Matsumura S; Ajima K; Yudasaka M; Iijima S; Shiba K
Mol Pharm; 2007; 4(5):723-9. PubMed ID: 17685580
[TBL] [Abstract][Full Text] [Related]
4. Targeted killing of cancer cells in vivo and in vitro with IGF-IR antibody-directed carbon nanohorns based drug delivery.
Li N; Zhao Q; Shu C; Ma X; Li R; Shen H; Zhong W
Int J Pharm; 2015 Jan; 478(2):644-54. PubMed ID: 25510600
[TBL] [Abstract][Full Text] [Related]
5. Single-walled carbon nanohorns as drug carriers: adsorption of prednisolone and anti-inflammatory effects on arthritis.
Nakamura M; Tahara Y; Ikehara Y; Murakami T; Tsuchida K; Iijima S; Waga I; Yudasaka M
Nanotechnology; 2011 Nov; 22(46):465102. PubMed ID: 22024636
[TBL] [Abstract][Full Text] [Related]
6. Drug-loaded carbon nanohorns: adsorption and release of dexamethasone in vitro.
Murakami T; Ajima K; Miyawaki J; Yudasaka M; Iijima S; Shiba K
Mol Pharm; 2004; 1(6):399-405. PubMed ID: 16028351
[TBL] [Abstract][Full Text] [Related]
7. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats.
Yokoe J; Sakuragi S; Yamamoto K; Teragaki T; Ogawara K; Higaki K; Katayama N; Kai T; Sato M; Kimura T
Int J Pharm; 2008 Apr; 353(1-2):28-34. PubMed ID: 18082345
[TBL] [Abstract][Full Text] [Related]
8. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
[TBL] [Abstract][Full Text] [Related]
9. Immobilization of a carbon nanomaterial-based localized drug-release system using a bispecific material-binding peptide.
Kokubun K; Matsumura S; Yudasaka M; Iijima S; Shiba K
Int J Nanomedicine; 2018; 13():1643-1652. PubMed ID: 29588591
[TBL] [Abstract][Full Text] [Related]
10. Engineered redox-responsive PEG detachment mechanism in PEGylated nano-graphene oxide for intracellular drug delivery.
Wen H; Dong C; Dong H; Shen A; Xia W; Cai X; Song Y; Li X; Li Y; Shi D
Small; 2012 Mar; 8(5):760-9. PubMed ID: 22228696
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
[TBL] [Abstract][Full Text] [Related]
12. Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery.
Liu Z; Sun X; Nakayama-Ratchford N; Dai H
ACS Nano; 2007 Aug; 1(1):50-6. PubMed ID: 19203129
[TBL] [Abstract][Full Text] [Related]
13. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-loaded (PEG)₃-PLA nanopolymersomes: effect of solvents and process parameters on formulation development and in vitro study.
Ayen WY; Garkhal K; Kumar N
Mol Pharm; 2011 Apr; 8(2):466-78. PubMed ID: 21288047
[TBL] [Abstract][Full Text] [Related]
15. Prevention of carbon nanohorn agglomeration using a conjugate composed of comb-shaped polyethylene glycol and a peptide aptamer.
Matsumura S; Sato S; Yudasaka M; Tomida A; Tsuruo T; Iijima S; Shiba K
Mol Pharm; 2009; 6(2):441-7. PubMed ID: 19718797
[TBL] [Abstract][Full Text] [Related]
16. Stimuli-responsive PEGylated prodrugs for targeted doxorubicin delivery.
Xu M; Qian J; Liu X; Liu T; Wang H
Mater Sci Eng C Mater Biol Appl; 2015 May; 50():341-7. PubMed ID: 25746279
[TBL] [Abstract][Full Text] [Related]
17. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
18. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2.
Ren J; Shen S; Wang D; Xi Z; Guo L; Pang Z; Qian Y; Sun X; Jiang X
Biomaterials; 2012 Apr; 33(11):3324-33. PubMed ID: 22281423
[TBL] [Abstract][Full Text] [Related]
19. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
20. Effects of liposomal phospholipids and lipid transport-related protein on the intracellular fate of encapsulated doxorubicin.
Un K; Sakai-Kato K; Kawanishi T; Okuda H; Goda Y
Mol Pharm; 2014 Feb; 11(2):560-7. PubMed ID: 24383572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
